NASDAQ:HEPA Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis $0.06 +0.00 (+3.33%) As of 02:08 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock About Hepion Pharmaceuticals Stock (NASDAQ:HEPA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hepion Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.06▼$0.0750-Day Range$0.04▼$0.1052-Week Range$0.03▼$0.11Volume13,498 shsAverage Volume20,820 shsMarket Capitalization$708.97 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Hepion Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases. The company harnesses epigenetic and autophagy‐modulating approaches to address high unmet medical needs in conditions such as nonalcoholic steatohepatitis (NASH), fibrosis and hepatocellular carcinoma. Hepion’s research platform is designed to identify and advance small molecules that can halt or reverse liver damage by targeting key pathways involved in inflammation, cellular stress and tissue remodeling. The company’s lead therapeutic candidate, CRV431, is a cyclophilin inhibitor being evaluated in Phase 2 clinical trials for the treatment of NASH with bridging fibrosis. CRV431 has demonstrated the potential to reduce inflammation, fibrosis and lipid accumulation in preclinical models. In addition to CRV431, Hepion’s pipeline includes early‐stage compounds aimed at inhibiting VPS34, an enzyme involved in autophagy, which may offer complementary mechanisms to improve liver function and slow disease progression. Hepion collaborates with academic institutions and contract research organizations to advance its programs from preclinical development into human studies. Hepion Pharmaceuticals is headquartered in the United States and conducts multi‐center trials across North America and Europe. The company is led by a management team with extensive experience in pharmaceutical development, regulatory strategy and commercialization. Hepion seeks to leverage its scientific expertise and strategic partnerships to deliver safe and effective therapies for patients suffering from chronic liver disorders.AI Generated. May Contain Errors. Read More Receive HEPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HEPA Stock News HeadlinesHepion Pharmaceuticals Announces Private Placement Financing AgreementApril 22, 2026 | tipranks.comHepion Finalizes CEO Separation Agreement Amid Leadership TransitionApril 14, 2026 | tipranks.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.June 4 at 1:00 AM | Porter & Company (Ad)Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular CarcinomaMarch 3, 2026 | globenewswire.comHepion Pharmaceuticals CFO John Brancaccio resigns effective MondayJuly 1, 2025 | investing.comHepion Pharmaceuticals Successfully Completes Application to the OTCQBJune 25, 2025 | globenewswire.comHEPA Hepion Pharmaceuticals, Inc.CJune 22, 2025 | seekingalpha.comHepion Pharmaceuticals Appoints Kaouthar Lbiati As Interim CEOJune 17, 2025 | nasdaq.comSee More Headlines HEPA Stock Analysis - Frequently Asked Questions How have HEPA shares performed this year? Hepion Pharmaceuticals' stock was trading at $0.06 at the beginning of the year. Since then, HEPA shares have increased by 3.3% and is now trading at $0.0620. How were Hepion Pharmaceuticals' earnings last quarter? Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) posted its quarterly earnings data on Sunday, November, 15th. The company reported ($690.00) EPS for the quarter, missing analysts' consensus estimates of ($510.00) by $180.00. When did Hepion Pharmaceuticals' stock split? Shares of Hepion Pharmaceuticals reverse split before market open on Tuesday, March 18th 2025.The 1-50 reverse split was announced on Friday, March 14th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Hepion Pharmaceuticals? Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hepion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hepion Pharmaceuticals investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), FuelCell Energy (FCEL), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD) and Meta Platforms (META). Company Calendar Last Earnings11/15/2020Today6/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HEPA CIK1583771 Webwww.hepionpharma.com Phone(732) 902-4000Fax732-902-4100Employees20Year Founded2013Profitability EPS (Trailing Twelve Months)($72.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-812.56% Return on Assets-207.31% Debt Debt-to-Equity RatioN/A Current Ratio1.30 Quick Ratio1.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book0.05Miscellaneous Outstanding Shares11,435,000Free Float6,631,000Market Cap$708.97 thousand OptionableNo Data Beta1.52 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:HEPA) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredWhere did Vanguard quietly put $101 billion?Tech investor George Gilder spent 40 years identifying paradigm shifts before they went mainstream - flagging ...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
